Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)
Introduction
Phosphodiesterases (PDEs) are intracellular enzymes involved in the inactivation of the second messengers cAMP and cGMP [1]. The subtype PDE4 is expressed in smooth muscle cells and inflammatory cells and as such represents a potential target in asthma and chronic obstructive pulmonary disease (COPD) [2], [3]. Inhibition of PDE4 results in increases in intracellular cAMP which in turn results in smooth muscle relaxation and suppression of activation of inflammatory cells [1], [2]. In vivo administration of ‘second generation’ PDE4 inhibitors such as cilomilast has been shown to be clinically effective. In patients with severe asthma using inhaled steroids, PDE4 inhibition by a single dose of cilomilast provides rapid bronchodilation which is sustained during prolonged treatment [4]. Furthermore, in COPD patients with poorly reversible lung function, PDE4 inhibition by cilomilast during 6 weeks of treatment results in additional bronchodilation, on top of β2-agonist use [5].
BAY 19-8004 is a novel, selective second generation PDE4 inhibitor which is under development for the treatment of patients with asthma or COPD [6]. Phase I studies in healthy volunteers have indicated that once daily dosing with 5 mg of BAY 19-8004 is optimal [6]. To date, there have been no studies reporting on the effects of BAY 19-8004 in patient populations. Therefore, the aim of this study was to investigate the acute effect of a single dose of BAY 19-8004 on lung function in patients with asthma and in patients with COPD. Furthermore, we aimed to examine whether such acute bronchodilation was sustained during 1 week of treatment with BAY 19-8004 and whether this effect was associated with changes in markers of inflammation. To that end, both patient groups were treated for 1 week with PDE4 inhibitor BAY 19-8004 (5 mg once daily) or placebo using a cross-over design. Lung function was recorded during 7 h following the first (acute effect) and last dose (medium term effect) of study medication. Markers of inflammation were studied in induced sputum samples, collected following 1 week of treatment. Finally, to evaluate systemic effects of BAY 19-8004, whole blood was stimulated ex vivo with bacterial lipopolysaccharide (LPS) and subsequent cytokine production was measured.
Section snippets
Patients
Eleven patients with COPD (3 female) and seven patients with asthma (3 female), aged between 18 and 80 years, were recruited for this study. Patients had to fulfill the following inclusion criteria. COPD: a clinical diagnosis of the disease [7], post-bronchodilator FEV1 40–70% of predicted value, reversibility in FEV1 following inhalation of 400 μg of salbutamol <12% from pre-bronchodilator value and smoking history ≥20 pack years. Asthma: a clinical diagnosis of the disease [8],
Results
All patients completed the study. Patient characteristics at baseline are shown in Table 1, Table 2.
Discussion
The results of this study show that 1 week of treatment with the novel PDE4 inhibitor BAY 19-8004, 5 mg once daily, reduces albumin and ECP levels in induced sputum of patients with COPD. These reductions in inflammatory mediators were not accompanied by acute or medium term changes in lung function, nor in cell numbers in induced sputum. Furthermore, BAY 19-8004 treatment did not change any of the endpoints in patients with asthma. These results may suggest that in patients with COPD treated
Acknowledgements
This study was supported by Bayer B.V., Mijdrecht, the Netherlands. The authors thank Hilly van der Veen for performing differential cell counts, and Renate Verhoosel and Bram van der Linden for performing ELISAs.
References (28)
Cyclic nucleotide phosphodiesterases
J Allergy Clin Immunol
(2001)- et al.
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study
Lancet
(2001) - et al.
Phosphodiesterase 4 inhibitors for the treatment of COPD
Chest
(2002) - et al.
Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
Pulm Pharmacol Ther
(2003) - et al.
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial
Lancet
(1999) Phosphodiesterase isozymes: molecular targets for novel antiasthma agents
Am J Respir Crit Care Med
(1998)- et al.
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease
Curr Opin Allergy Clin Immunol
(2002) - et al.
SB207499 improves pulmonary function in patients with asthma receiving concomitant inhaled corticosteroids
Eur Respir J
(1999) - et al.
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force
Eur Respir J
(1995) - Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. NIH...
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summery
Am J Respir Crit Care Med
Reference spirometric values using techniques and equipment that meet ATS recommendations
Am Rev Respir Dis
Repeatability of cellular and soluble markers in induced sputum from patients with asthma
Eur Respir J
Cited by (34)
cAMP-PDE signaling in COPD: Review of cellular, molecular and clinical features
2023, Biochemistry and Biophysics ReportsIdentification of long non-coding RNA and circular RNA in mice after intra-tracheal instillation with fine particulate matter
2019, ChemosphereCitation Excerpt :To explore the underlying mechanism and therapeutic method of the adverse effects caused by PM2.5 exposure is very important as it cannot be eliminated completely in a short time. Chronic inflammation plays a crucial role in the pathogenesis and development of many respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma (Grootendorst et al., 2003). Once inhaled, particles deposit in lung from airway to alveoli and diffuse in blood which induces respiratory and systematic inflammation (Bernstein et al., 2004; Brunekreef and Holgate, 2002).
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: Findings from four clinical trials
2013, The Lancet Respiratory MedicineCitation Excerpt :Further supporting this notion, PDE3 was recently reported to be upregulated in the airways of patients with asthma.24 Although we cannot formally exclude a contributory role of PDE4 inhibition in the acute bronchodilator response after one dose of RPL554, such an effect of PDE4 inhibition seems highly unlikely because neither inhaled25 nor oral26,27 PDE4 inhibitors produce an acute increase in FEV1 in human beings. Taken together, these data suggest that PDE3 plays an important part in maintenance of airway tone in healthy and diseased airways.
Roflumilast: A Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease
2012, Clinical TherapeuticsCitation Excerpt :In this population, roflumilast reduced inflammatory cells and markers of inflammation in the sputum and provided modest improvements in FEV1. Improvement in lung function is likely due to the effects on inflammation, as PDE4 inhibitors have not exhibited direct bronchodilating effects in previous studies.13,19,20 Since roflumilast is metabolized by CYP 3A4, 2C19, and 1A2, multiple possibilities for drug-drug interactions exist.
Differential effects of PDE4 inhibitors on cortical neurons and T-lymphocytes
2008, Journal of Pharmacological SciencesClinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long-acting beta-2-agonist
2021, Fundamental and Clinical Pharmacology